MS Treatments

The below disease modifying treatments (DMT’s) are available for the treatment of MS in New Zealand.


First line treatments for Relapsing Remitting MS (funded)

Ocrevus® (Ocrelizumab)

Gilenya® (Fingolimod)

Aubagio® (teriflunomide)

Tecfidera® (Dimethyl fumarate)

Tysabri® (Natalizumab)


Second line treatments for Relapsing Remitting MS (funded)

Copaxone® (glatiramer acetate)



DMTs for Primary Progressive MS (funded)

Ocrevus® (Ocrelizumab)


Disease Modifying Treatment Special Authority Criteria

Information on the entry and exit criteria for the PHARMAC funded treatments and application process.


Other disease modifying treatments (DMTs) and symptom management medications (available in NZ but not-funded)

Mavenclad® (Cladribine)

Sativex® (Nabiximols)

Fampyra® (fampridine)

LDN-Low-Dose Naltrexone (LDN)



Disease modifying treatments (DMTs) not currently available in NZ

Stem Cell Treatment


Further information

There are many more treatments out there to look into. MS Trust have created a wonderful tool that lists some of the more common drugs and treatments and the symptoms for which they can be used.

MS Trust – Treatment finder tool



Stem Cell Transplant
Managing and Treating MS

Stem cell therapy is any treatment that uses or targets stem cells

Clinical Trials
What are they?

Information to help you decide

Research and Studies

News and updates